Millie: Search Results

Search Results

50 results

Your search is now limited to «Clinical Trials» expert search.

The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of diabetic retinopathy, expected to advance into a Phase 1 study in 2020.

More from GlobeNewswire:

Hua Medicine’s Pivotal Phase III Monotherapy Trial of Dorzagliatin, a Dual-Acting Glucokinase Modulator, Achieves Primary Efficacy Endpoint in Patients with Type 2 Diabetes, 11/11/2019 11:00

Sanofi : Positive results in Phase 3 trial for Toujeo® in children and adolescents with type 1 diabetes, 11/04/2019 01:00

EastGate Biotech Receives Regulatory Approval to Initiate a Phase III 90-day Clinical Trial on Insugin, Its Liquid Insulin Mouth Rinse Solution, 09/25/2019 09:00

View All 7

The AAT intervention showed promise in the subgroup of adolescents with recent-onset type 1 diabetes.

More from FeedNavigator (EU):

Exploratory analysis of comparative clinical trials used for marketing approval in patients with type 2 diabetes in Japan, 11/24/2019 06:02

A Twelve‐Week, Randomized, Double‐Blind, Placebo‐Controlled, Four‐Arm Dose‐Finding Phase 2 Study Evaluating Bexagliflozin as a Monotherapy for Adults with Type 2 Diabetes, 11/21/2019 10:37

Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT‐5): 52‐week results from a randomized, open‐label, phase III clinical trial, 11/20/2019 10:37

View All 12

Arecor announces positive headline results for first Phase I clinical trial of AT247, a novel formulation of insulin.

More from Cambridge Network:

Dosing complete in Phase I clinical trial of ultra-rapid acting insulin product candidate for diabetes, 10/04/2019 06:24

View All 2

About the Phase 3 TIMES Program TIMES (Trials of Imeglimin for Efficacy and Safety), the Phase 3 program for Imeglimin for the treatment of type 2 diabetes in Japan, consists of three pivotal trials involving over 1,100 patients ...

More from Business Wire:

Exelixis’ Collaborator Daiichi Sankyo Announces Positive Results From Phase 3 Pivotal Trial of Esaxerenone in Patients With Diabetic Nephropathy, 11/07/2019 20:01

Xeris Pharmaceuticals Begins Dosing Patients in a Phase 2 Clinical Trial Evaluating Its Novel Fixed-Ratio Co-Formulation of Pramlintide-Insulin for Diabetes, 09/19/2019 08:00

Poxel Announces Detailed Imeglimin Phase 3 TIMES 1 Results Presented at 55th Annual Meeting of the European Association for the Study of Diabetes, 09/18/2019 07:00

View All 4

The trial protocol was approved by all relevant institutional review boards/independent ethics committees, and the trial was conducted in accordance with ICH Good Clinical Practice guidelines and the Declaration of Helsinki.

More from American Diabetes Journals:

Divergent Hypoglycemic Effects of Hepatic-Directed Prandial Insulin: A 6-Month Phase 2b Study in Type 1 Diabetes, 10/21/2019 15:00

View All 2

Oral insulin demonstrates safety, efficacy in phase 2b trial Adults with type 2 diabetes assigned an oral formulation of human insulin achieved a clinically meaningful reduction in HbA1c compared with those assigned placebo, according to a press release from Oramed Pharmaceuticals ...

More from Healio News:

Oral insulin demonstrates safety, efficacy in phase 2b trial, 11/12/2019 15:04

View All 2

Condition : Diabetic Kidney Disease Interventions : Drug: MEDI3506; Drug: Placebo Sponsor : AstraZeneca Not yet recruiting.

More from ClinicalTrials.gov:

Pilot and Phase 2 Study of the Efficacy of a Treatment Protocol With Dexamethasone Implant Loading Dose in Patients With Diabetic Macular Edema (LOADEX), 10/04/2019 07:02

PHASE 1, OPEN-LABEL SAFETY STUDY OF UMBILICAL CORD LINING MESENCHYMAL STEM CELLS (CORLICYTE®) TO HEAL CHRONIC DIABETIC FOOT ULCERS, 09/26/2019 08:48

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled 14-week Study of DS-5565 in Chinese Patients With Diabetic Peripheral Neuropathic Pain, 09/19/2019 08:00

View All 6

The Phase IIb data has shown efficacy in patients whose diabetes was inadequately controlled either on metformin alone, or metformin with up to two additional oral antihyperglycemic agents, with the latter group constituting the majority.

More from PR Newswire:

Positive results in Phase 3 trial for Toujeo® in children and adolescents with type 1 diabetes, 11/04/2019 07:00

Microbion Corporation Announces Results from Randomized, Double Blind, Placebo-Controlled Phase 1b Trial of Pravibismane (MBN-101) for Treatment of Moderate to Severe Chronic Infected Diabetic Foot Ulcers, 10/28/2019 08:00

Bird Rock Bio Announces Successful Completion of Phase 1B Safety Study and Readiness for Phase 2B Study of Nimacimab in Patients with Diabetic Kidney Disease, 10/17/2019 09:00

View All 5

In Japan, approximately 10 million people, or 12.1 % of the population, are estimated to have diabetes, with a growing incidence.

A little under two months since their latest setback in diabetes R&D as their dominant perch in the market is shaken by severe headwinds, Sanofi had some positive results to report Monday from a Phase III trial applying its Lantus insulin followup in childhood and adolescent type 1 diabetes ...

Promising Phase 3 data for Sanofi's Toujeo secures CHMP recommendation of label expansion in type 1 diabetes.

These programs include olinciguat in Phase 2 development for sickle cell disease, IW-6463 in Phase 1 development for serious and orphan central nervous system diseases, and two preclinical programs targeting serious liver and lung diseases, respectively.

More from Benzinga:

Diasome Announces Publication of Phase 2b Results in Diabetes Care, 09/24/2019 10:51

View All 2

The results of the phase 2 trial, where a drug or treatment’s effectiveness is tested on human patients, were unveiled at a medical conference held in Spain.

In phase 3-1 trial, the company tried to reaffirm the pain reduction effect of the drug, which it had confirmed in phase 2 clinical trial.

Final results from a phase 3 study preceded FDA approval of oral semaglutide. .

Dr. Allen Davidoff stated, “In the opinion of XORTX, TMX-049 is the leading next generation candidate xanthine oxidase inhibitor with a desirable combination of strong clinical safety record and potent uric acid lowering capability.

Graybug Vision initiates clinical trial in macular edema secondary to diabetic macular edema or retinal vein occlusion.

On this page, you see the results of the search you have run. You may also view the following:

Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format.
View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.
Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.
Show or hide the record’s caption (content description).
Show actions that can be made with the search result record.
Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications